94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1546813
This article is part of the Research TopicInnovative Biomarkers for Chronic Myeloid Leukemia: Detection, and Therapy.View all articles
The biology of Chronic Myeloid Leukemia: an overview of the new insights and biomarkers
Provisionally accepted- 1Chair of Hematology, University of Siena, Azienda Ospedaliera Universitaria, 53100 Siena, Italy, Siena, Italy
- 2Chair of Hematology, Dep of Clinical and Experimental Sciences, University of Brescia - Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy, Brescia, Italy
- 3Laboratorio CREA (Centro di Ricerca Emato-oncologica AIL), ASST-Spedali Civili, Brescia, Italy, Brescia, Italy
- 4National Center for Gene Therapy and Drugs Based on RNA Technology, Padova, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic myeloid leukemia is one of the onco-hematologic diseases in which the identification of disease markers and therapeutic advances have been particularly impactful. Despite this, significant gaps remain in our understanding of disease pathogenesis, progression, mechanisms of immune escape, and resistance to standard therapies. Recently, advances in technology and biological knowledge have drawn attention to several promising areas of research. Among these, leukemic stem cells, miRNAs, extracellular vesicles, and additional BCR::ABL1 mutations, with particular reference to the ASXL1 gene, have been the most extensively investigated. In this review we summarized and critically commented the main findings on these key topics over the past 5 years, evaluating their potential impact on patient management and their role in the development of new therapeutic strategies.
Keywords: CML, Biological Markers, BCR::ABL1, ASXL1, EVS, CD26, Leukemic stem cell, miRNA
Received: 17 Dec 2024; Accepted: 17 Apr 2025.
Copyright: © 2025 Sicuranza, Cavalleri and Bernardi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Alessia Cavalleri, Chair of Hematology, Dep of Clinical and Experimental Sciences, University of Brescia - Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy, Brescia, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.